Serum concentrations of IGF-1 in patients from Israel indicated that this biomarker could be useful for predicting UM metastases, as IGF-1 was significantly lower in subjects with metastatic tumors compared to subjects who recovered from the disease 10 or more years ago (or even more) than in control healthy subjects [118]. The gene discussed is IGF1; the disease is metastatic neoplasm.